Diligence memo · auto-generated · as of July 2, 2026

Castle Creek Pharmaceuticals, LLC

Castle Creek Pharmaceuticals, LLC looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Castle Creek Pharmaceuticals, LLC operates in Pharmaceuticals, based in BEDMINSTER.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Castle Creek Pharmaceuticals, LLC has raised $48M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $48M on 2016-09-29.

Most recent recorded round closed around 2016-09-29.

Valuation (modeled)modeled

Provath models Castle Creek Pharmaceuticals, LLC at approximately $1.7B (range $156M–$4.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.73× the median modeled value of Series C Pharmaceuticals companies in 2016–2018 (32 peers) — value vs value, same stage and era. Within the normal band (73% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 9.8 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 81% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 93% of those peers.

Closest niche peers: Amplyx Pharmaceuticals, Inc., Ligand Pharmaceuticals Inc, Homology Medicines, Inc., KSQ Therapeutics, Inc., TP Therapeutics, Inc..

Peoplefiled

6 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.